Obesity Action Coalition (official site)

Related guides

• FDA's proposal to keep compounded GLP-1s off the 503B bulks list — and how to comment — In May 2026 the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B compounding bulks list — a decision that affects how compounded GLP-1s can be made. The public comment period is open (as reported, through July 30, 2026). Here's what the proposal is, why it matters for access, and how to submit a comment.
• The Obesity Society — A scientific and clinical authority on obesity research, treatment, and policy, bringing together researchers, clinicians, and advocates.
• The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973): what it is and why it matters — TROA is the primary federal bill aimed at fixing Medicare's exclusion of obesity medications — reintroduced repeatedly for over a decade with bipartisan support, but not yet passed. Here's what it would actually change.
• Escalation paths beyond your insurer: commissioners, ombudsmen, and external review — When your insurer's internal appeals are exhausted, you're not out of options. Here's who else you can turn to — state regulators, independent reviewers, and patient ombudsmen — and when each applies.
• What to say when your employer's benefits team says no — A "no" from HR or benefits isn't always final — it often just means the current plan year's decision has been made. Here's how to respond productively and keep the door open for next year.
• How to write an effective insurance appeal letter — A strong appeal letter directly rebuts the specific denial reason with specific documentation — not a general plea for coverage. Here's a structure to work from.